Lipid Nanoparticle Aerosol Formulation for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current aerosol formulations of lipid or lipidoid nanoparticles for nucleic acid delivery by inhalation face challenges such as inefficient deposition in the respiratory tract, patient compliance issues due to prolonged inhalation times, and stability concerns during nebulization, which affect the integrity and efficacy of the nucleic acid.
Innovation Solution
An aqueous suspension formulation of lipid or lipidoid nanoparticles suspended in a poly(ethylene oxide)-poly(propylene oxide) block copolymer solution, containing a nucleic acid and an ionizable lipid, which can be efficiently nebulized while maintaining particle integrity and transfection efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipid or lipidoid nanoparticles are used for nucleic acid delivery by inhalation, then the nucleic acid can be delivered to target cells in the respiratory tract, but the formulation suffers from aggregation during nebulization and loss of particle integrity
Solution Approach 1:
A surfactant is introduced as an intermediary substance to prevent aggregation of lipid or lipidoid nanoparticles during nebulization. The surfactant acts as a mediator between the nanoparticles and the nebulization process, reducing surface tension and preventing particle aggregation, thereby maintaining particle integrity and stability throughout aerosol generation and delivery to the respiratory tract.
2Reliability
If inhalation time is extended to ensure effective dose deposition, then therapeutic efficacy is improved, but patient compliance deteriorates due to prolonged inhalation burden
Solution Approach 1:
The formulation is pre-optimized with specific surfactant concentrations and nanoparticle characteristics that enable efficient deposition during brief inhalation events. By preliminarily adjusting the formulation properties (surfactant type, concentration, nanoparticle size distribution), the system achieves effective dose delivery in reduced time, eliminating the need for prolonged inhalation and thereby improving patient compliance while maintaining therapeutic efficacy.
3Ease of operation
If conventional aerosol formulations are used for nucleic acid delivery, then administration by inhalation is convenient, but the formulation loses efficacy upon nebulization due to instability
Solution Approach 1:
Critical formulation parameters are systematically optimized including surfactant concentration (0.01-10% w/v), nanoparticle size distribution (10-500 nm), and lipid composition ratios. These parameter changes enable the formulation to withstand nebulization stresses while maintaining transfection efficiency. The optimized parameters create a formulation that is both nebulization-stable and biologically effective, resolving the contradiction between administration convenience and therapeutic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation allows for improved resistance to aggregation during nebulization and maintains the transfection efficiency of the nucleic acid, enabling effective delivery to the respiratory tract within a reasonable time frame.
Implementation Method 1
an aqueous suspension formulation of lipid or lipidoid nanoparticles suspended in a poly(ethylene oxide)-poly(propylene oxide) block copolymer solution
Implementation Method 2
An aqueous suspension formulation for aerosol formation, said suspension formulation comprising lipid or lipidoid nanoparticles which are suspended in an aqueous vehicle solution
Data Source
AI summary
The invention relates to an aqueous suspension formulation for aerosol formation, said suspension formulation comprising lipid or lipidoid nanoparticles which are suspended in an aqueous vehicle solution,wherein the lipid or lipidoid nanoparticles comprise the following components (a) and (b):(a) a nucleic acid and(b) an ionizable lipid or an ionizable lipidoid;and wherein the aqueous vehicle solution comprises a triblock copolymer which contains one poly(propylene oxide) block and two poly(ethylene oxide) blocks. Moreover, the invention relates to an aerosol obtained from the formulation for aerosol formation.